| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents, Phytogenic | 23 | 2024 | 626 | 4.660 |
Why?
|
| Paclitaxel | 28 | 2024 | 1736 | 3.950 |
Why?
|
| Nanoparticles | 32 | 2024 | 1943 | 3.760 |
Why?
|
| Lung Neoplasms | 63 | 2024 | 13262 | 3.710 |
Why?
|
| Thoracic Surgery | 11 | 2024 | 725 | 3.270 |
Why?
|
| Spectroscopy, Near-Infrared | 15 | 2020 | 741 | 2.900 |
Why?
|
| Thoracic Surgical Procedures | 8 | 2024 | 348 | 2.750 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 29 | 2024 | 5251 | 2.570 |
Why?
|
| Mesothelioma | 15 | 2023 | 807 | 2.550 |
Why?
|
| Indocyanine Green | 8 | 2020 | 236 | 1.790 |
Why?
|
| Lymph Nodes | 15 | 2017 | 3486 | 1.720 |
Why?
|
| Drug Delivery Systems | 27 | 2024 | 2221 | 1.660 |
Why?
|
| Polymers | 20 | 2024 | 1621 | 1.630 |
Why?
|
| Drug Carriers | 14 | 2024 | 709 | 1.520 |
Why?
|
| Pneumonectomy | 19 | 2023 | 1111 | 1.430 |
Why?
|
| Sentinel Lymph Node Biopsy | 8 | 2018 | 733 | 1.370 |
Why?
|
| Glycerol | 5 | 2024 | 276 | 1.270 |
Why?
|
| Peritoneal Neoplasms | 5 | 2022 | 707 | 1.250 |
Why?
|
| Nanotechnology | 5 | 2016 | 709 | 1.220 |
Why?
|
| Lymphatic Metastasis | 12 | 2020 | 2943 | 1.080 |
Why?
|
| Bone Marrow Cells | 6 | 2020 | 2414 | 0.950 |
Why?
|
| Sarcoma | 4 | 2023 | 1786 | 0.830 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2022 | 167 | 0.810 |
Why?
|
| Radiation Chimera | 7 | 2004 | 216 | 0.790 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2022 | 9276 | 0.700 |
Why?
|
| Thoracic Surgery, Video-Assisted | 5 | 2023 | 277 | 0.680 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 16939 | 0.650 |
Why?
|
| Pleural Neoplasms | 4 | 2020 | 609 | 0.620 |
Why?
|
| Physician's Role | 2 | 2019 | 918 | 0.590 |
Why?
|
| Forecasting | 4 | 2024 | 2932 | 0.580 |
Why?
|
| Polyesters | 9 | 2024 | 372 | 0.580 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2006 | 801 | 0.580 |
Why?
|
| Specialty Boards | 1 | 2019 | 235 | 0.580 |
Why?
|
| Certification | 2 | 2019 | 421 | 0.570 |
Why?
|
| Biomedical Research | 4 | 2024 | 3426 | 0.570 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 14 | 2017 | 400 | 0.550 |
Why?
|
| Carcinoma | 5 | 2022 | 2331 | 0.540 |
Why?
|
| Radiosurgery | 6 | 2024 | 1343 | 0.500 |
Why?
|
| Neoplasm Staging | 20 | 2023 | 11152 | 0.490 |
Why?
|
| Pinocytosis | 1 | 2015 | 62 | 0.490 |
Why?
|
| Bone Marrow Transplantation | 11 | 2006 | 2693 | 0.490 |
Why?
|
| Research Support as Topic | 3 | 2019 | 699 | 0.480 |
Why?
|
| Diagnostic Imaging | 4 | 2013 | 3527 | 0.470 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 2363 | 0.470 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2014 | 76 | 0.470 |
Why?
|
| Animals | 77 | 2024 | 167963 | 0.470 |
Why?
|
| Humans | 143 | 2024 | 760621 | 0.460 |
Why?
|
| Physicians, Women | 4 | 2016 | 495 | 0.460 |
Why?
|
| Research Personnel | 1 | 2019 | 582 | 0.460 |
Why?
|
| Fluorescent Dyes | 10 | 2017 | 1913 | 0.460 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2014 | 47 | 0.450 |
Why?
|
| Coloring Agents | 4 | 2020 | 562 | 0.440 |
Why?
|
| Mice | 48 | 2023 | 81208 | 0.440 |
Why?
|
| Lymphocele | 1 | 2012 | 19 | 0.430 |
Why?
|
| Societies, Medical | 3 | 2024 | 3905 | 0.430 |
Why?
|
| Lung | 10 | 2021 | 9994 | 0.420 |
Why?
|
| Career Choice | 1 | 2019 | 754 | 0.410 |
Why?
|
| Isoantigens | 3 | 2006 | 552 | 0.410 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 1392 | 0.410 |
Why?
|
| Biocompatible Materials | 7 | 2023 | 1689 | 0.400 |
Why?
|
| Graft Survival | 11 | 2007 | 3794 | 0.400 |
Why?
|
| Forkhead Transcription Factors | 3 | 2008 | 1612 | 0.390 |
Why?
|
| Neoplasms, Experimental | 3 | 2018 | 1229 | 0.380 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 377 | 0.380 |
Why?
|
| Mediastinum | 1 | 2012 | 266 | 0.380 |
Why?
|
| Delayed-Action Preparations | 5 | 2016 | 961 | 0.380 |
Why?
|
| Antineoplastic Agents | 12 | 2024 | 13630 | 0.380 |
Why?
|
| Lymphatic Abnormalities | 1 | 2012 | 132 | 0.370 |
Why?
|
| Transplantation Tolerance | 2 | 2007 | 605 | 0.370 |
Why?
|
| Bronchoscopy | 5 | 2021 | 911 | 0.370 |
Why?
|
| Feasibility Studies | 9 | 2022 | 5201 | 0.370 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 3202 | 0.360 |
Why?
|
| Molecular Imaging | 1 | 2017 | 818 | 0.360 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2011 | 123 | 0.360 |
Why?
|
| Esophageal Neoplasms | 3 | 2024 | 1648 | 0.360 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 247 | 0.360 |
Why?
|
| Spheroids, Cellular | 3 | 2017 | 329 | 0.360 |
Why?
|
| Luminescent Measurements | 1 | 2012 | 378 | 0.350 |
Why?
|
| Thoracic Outlet Syndrome | 2 | 2023 | 97 | 0.350 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2010 | 43 | 0.350 |
Why?
|
| Gene Transfer Techniques | 2 | 2016 | 1204 | 0.350 |
Why?
|
| Leadership | 1 | 2019 | 1371 | 0.340 |
Why?
|
| Micelles | 2 | 2023 | 192 | 0.330 |
Why?
|
| Clinical Competence | 2 | 2019 | 4783 | 0.320 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 4902 | 0.320 |
Why?
|
| Pharmaceutical Preparations | 3 | 2022 | 1091 | 0.310 |
Why?
|
| Breast Neoplasms | 7 | 2024 | 21025 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2007 | 5649 | 0.310 |
Why?
|
| Female | 74 | 2024 | 391270 | 0.300 |
Why?
|
| Neck | 1 | 2012 | 731 | 0.300 |
Why?
|
| Albumins | 1 | 2010 | 575 | 0.300 |
Why?
|
| Cytomegalovirus Infections | 1 | 2014 | 831 | 0.300 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2008 | 305 | 0.300 |
Why?
|
| Fetal Blood | 1 | 2014 | 1343 | 0.290 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 611 | 0.290 |
Why?
|
| Cunninghamella | 1 | 2006 | 1 | 0.280 |
Why?
|
| Zygomycosis | 1 | 2006 | 7 | 0.280 |
Why?
|
| Mice, Nude | 6 | 2022 | 3607 | 0.280 |
Why?
|
| T-Lymphocytes | 8 | 2022 | 10181 | 0.260 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2006 | 54 | 0.260 |
Why?
|
| Lung Diseases, Fungal | 1 | 2006 | 126 | 0.260 |
Why?
|
| Transplantation, Homologous | 10 | 2007 | 4810 | 0.250 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 168 | 0.250 |
Why?
|
| Immune Tolerance | 7 | 2006 | 2299 | 0.250 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2022 | 1765 | 0.240 |
Why?
|
| Predictive Value of Tests | 10 | 2017 | 15289 | 0.240 |
Why?
|
| Computer-Assisted Instruction | 1 | 2008 | 362 | 0.240 |
Why?
|
| Immunotherapy | 5 | 2024 | 4642 | 0.240 |
Why?
|
| Infrared Rays | 2 | 2020 | 246 | 0.240 |
Why?
|
| History, 21st Century | 3 | 2024 | 1575 | 0.230 |
Why?
|
| Quantum Dots | 5 | 2016 | 168 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 20 | 2015 | 22023 | 0.230 |
Why?
|
| Disease Models, Animal | 11 | 2022 | 18137 | 0.230 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2008 | 3075 | 0.230 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 2022 | 210 | 0.220 |
Why?
|
| Transplantation Chimera | 2 | 1996 | 595 | 0.220 |
Why?
|
| Porosity | 2 | 2022 | 349 | 0.220 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2016 | 1008 | 0.220 |
Why?
|
| Lung Transplantation | 4 | 2008 | 1305 | 0.220 |
Why?
|
| Cisplatin | 4 | 2017 | 1644 | 0.220 |
Why?
|
| Surface-Active Agents | 3 | 2023 | 150 | 0.220 |
Why?
|
| Receptors, IgG | 1 | 2006 | 559 | 0.210 |
Why?
|
| Lymphography | 2 | 2014 | 188 | 0.210 |
Why?
|
| Intraoperative Care | 4 | 2015 | 768 | 0.210 |
Why?
|
| Camptothecin | 5 | 2015 | 590 | 0.210 |
Why?
|
| Pulmonary Surfactants | 1 | 2023 | 161 | 0.210 |
Why?
|
| Cell Survival | 10 | 2017 | 5797 | 0.210 |
Why?
|
| Mediastinal Cyst | 1 | 2022 | 29 | 0.210 |
Why?
|
| Microscopy, Confocal | 3 | 2015 | 1972 | 0.210 |
Why?
|
| Prognosis | 13 | 2021 | 29658 | 0.210 |
Why?
|
| History, 20th Century | 3 | 2024 | 2773 | 0.210 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 2379 | 0.210 |
Why?
|
| Europe | 2 | 2019 | 3441 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3584 | 0.200 |
Why?
|
| Aneurysm | 1 | 2005 | 337 | 0.200 |
Why?
|
| Surgical Mesh | 2 | 2022 | 311 | 0.190 |
Why?
|
| Bronchoscopes | 1 | 2021 | 64 | 0.190 |
Why?
|
| Botulinum Toxins | 1 | 2023 | 188 | 0.190 |
Why?
|
| United States | 15 | 2024 | 72461 | 0.190 |
Why?
|
| Polyethylene Glycols | 3 | 2023 | 1189 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2006 | 749 | 0.190 |
Why?
|
| Health Education | 1 | 2008 | 1049 | 0.190 |
Why?
|
| Synthetic Biology | 1 | 2023 | 185 | 0.190 |
Why?
|
| Lymph Node Excision | 3 | 2017 | 1303 | 0.190 |
Why?
|
| Hemosiderosis | 1 | 2021 | 66 | 0.190 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 62 | 0.190 |
Why?
|
| Rhodamines | 3 | 2017 | 179 | 0.180 |
Why?
|
| Neoplasms | 9 | 2024 | 22072 | 0.180 |
Why?
|
| Prednisone | 2 | 2021 | 1565 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 20509 | 0.180 |
Why?
|
| Thymoma | 1 | 2022 | 187 | 0.180 |
Why?
|
| Retrospective Studies | 18 | 2024 | 80372 | 0.180 |
Why?
|
| Triazoles | 1 | 2006 | 904 | 0.180 |
Why?
|
| Ovarian Neoplasms | 3 | 2017 | 4878 | 0.180 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 8552 | 0.180 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 3844 | 0.180 |
Why?
|
| Fluorescence | 3 | 2013 | 751 | 0.180 |
Why?
|
| Lymphocyte Depletion | 3 | 1997 | 602 | 0.180 |
Why?
|
| Carrier Proteins | 2 | 2006 | 4938 | 0.180 |
Why?
|
| Neuroendocrine Cells | 1 | 2021 | 62 | 0.180 |
Why?
|
| Granzymes | 1 | 2022 | 276 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2023 | 3620 | 0.180 |
Why?
|
| Tissue Adhesives | 1 | 2021 | 173 | 0.170 |
Why?
|
| Male | 58 | 2024 | 359744 | 0.170 |
Why?
|
| Graft vs Host Disease | 5 | 2007 | 3025 | 0.170 |
Why?
|
| Transplantation Conditioning | 4 | 2006 | 1588 | 0.170 |
Why?
|
| Microspheres | 3 | 2013 | 787 | 0.170 |
Why?
|
| Thymus Neoplasms | 1 | 2022 | 274 | 0.170 |
Why?
|
| Mice, Inbred NOD | 2 | 2022 | 1837 | 0.170 |
Why?
|
| Middle Aged | 34 | 2023 | 220352 | 0.170 |
Why?
|
| Surgical Flaps | 1 | 2008 | 1669 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 5 | 2020 | 5351 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2011 | 1830 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2017 | 326 | 0.160 |
Why?
|
| Learning Curve | 1 | 2020 | 231 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2022 | 370 | 0.160 |
Why?
|
| Thymectomy | 1 | 1999 | 194 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2005 | 1097 | 0.160 |
Why?
|
| Chimera | 7 | 1999 | 453 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2007 | 4550 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 421 | 0.150 |
Why?
|
| Peritoneum | 2 | 2016 | 224 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2022 | 362 | 0.150 |
Why?
|
| Heart Transplantation | 5 | 2007 | 3224 | 0.150 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 1599 | 0.150 |
Why?
|
| Mammaplasty | 1 | 2008 | 1240 | 0.150 |
Why?
|
| Major Histocompatibility Complex | 2 | 1998 | 928 | 0.150 |
Why?
|
| Apoptosis | 4 | 2022 | 9501 | 0.150 |
Why?
|
| Electromagnetic Phenomena | 1 | 2018 | 161 | 0.150 |
Why?
|
| Graft Rejection | 5 | 2007 | 4426 | 0.150 |
Why?
|
| Hydrogen-Ion Concentration | 5 | 2016 | 2502 | 0.150 |
Why?
|
| Whole-Body Irradiation | 3 | 1998 | 433 | 0.150 |
Why?
|
| Ethanol | 2 | 2015 | 1323 | 0.150 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2017 | 87 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 789 | 0.140 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2015 | 276 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 4024 | 0.140 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2013 | 941 | 0.140 |
Why?
|
| Dendritic Cells | 1 | 2008 | 2725 | 0.140 |
Why?
|
| Survival Analysis | 8 | 2014 | 10182 | 0.140 |
Why?
|
| Aged | 29 | 2024 | 169152 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 9 | 2007 | 6216 | 0.140 |
Why?
|
| beta-Galactosidase | 1 | 2017 | 575 | 0.140 |
Why?
|
| Swine | 6 | 2012 | 5899 | 0.140 |
Why?
|
| Nanomedicine | 2 | 2020 | 288 | 0.140 |
Why?
|
| HLA Antigens | 6 | 1997 | 1368 | 0.140 |
Why?
|
| Quinolones | 1 | 2020 | 377 | 0.140 |
Why?
|
| Carcinoma, Lewis Lung | 3 | 2015 | 107 | 0.140 |
Why?
|
| Surface Properties | 6 | 2016 | 1161 | 0.140 |
Why?
|
| Rats, Inbred ACI | 3 | 2004 | 34 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8515 | 0.130 |
Why?
|
| Kinetics | 4 | 2018 | 6377 | 0.130 |
Why?
|
| Catheters | 1 | 2019 | 425 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2008 | 2064 | 0.130 |
Why?
|
| Immunization | 1 | 2000 | 1227 | 0.130 |
Why?
|
| Therapies, Investigational | 2 | 2020 | 112 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2019 | 504 | 0.130 |
Why?
|
| Postoperative Complications | 7 | 2015 | 15697 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 5 | 2022 | 6131 | 0.130 |
Why?
|
| Dendrimers | 1 | 2016 | 71 | 0.130 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 1996 | 293 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 39261 | 0.130 |
Why?
|
| Nanofibers | 1 | 2015 | 66 | 0.130 |
Why?
|
| Nanotubes, Carbon | 1 | 2016 | 71 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 3164 | 0.130 |
Why?
|
| Nanocapsules | 1 | 2016 | 92 | 0.130 |
Why?
|
| Pleural Cavity | 2 | 2005 | 25 | 0.120 |
Why?
|
| Occupational Diseases | 1 | 2023 | 1486 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3388 | 0.120 |
Why?
|
| Excipients | 1 | 2015 | 97 | 0.120 |
Why?
|
| Estrogens | 1 | 2021 | 1520 | 0.120 |
Why?
|
| Rats, Inbred F344 | 3 | 2004 | 825 | 0.120 |
Why?
|
| Biomimetic Materials | 1 | 2016 | 173 | 0.120 |
Why?
|
| Carboxylic Acids | 1 | 2015 | 90 | 0.120 |
Why?
|
| Technology, Pharmaceutical | 1 | 2015 | 84 | 0.120 |
Why?
|
| Mastectomy, Segmental | 1 | 2020 | 972 | 0.120 |
Why?
|
| Reproductive Behavior | 1 | 2014 | 27 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 1046 | 0.120 |
Why?
|
| Cyclophosphamide | 3 | 1997 | 2221 | 0.120 |
Why?
|
| Catheter Ablation | 1 | 2008 | 2758 | 0.120 |
Why?
|
| Polyglactin 910 | 1 | 2014 | 55 | 0.120 |
Why?
|
| Materials Testing | 2 | 2021 | 862 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2008 | 6218 | 0.120 |
Why?
|
| Thoracic Wall | 2 | 2014 | 199 | 0.120 |
Why?
|
| Immunophenotyping | 4 | 2006 | 1871 | 0.120 |
Why?
|
| Proportional Hazards Models | 5 | 2021 | 12531 | 0.120 |
Why?
|
| Stress, Mechanical | 2 | 2016 | 1666 | 0.110 |
Why?
|
| Treatment Outcome | 13 | 2024 | 65017 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2021 | 977 | 0.110 |
Why?
|
| Biopsy | 3 | 2021 | 6771 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 1152 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2020 | 1895 | 0.110 |
Why?
|
| Antilymphocyte Serum | 4 | 2000 | 482 | 0.110 |
Why?
|
| Patient Selection | 2 | 2021 | 4283 | 0.110 |
Why?
|
| Bronchial Fistula | 1 | 2013 | 83 | 0.110 |
Why?
|
| Birth Rate | 1 | 2014 | 168 | 0.110 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2012 | 57 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2016 | 248 | 0.110 |
Why?
|
| Thoracostomy | 1 | 2013 | 74 | 0.110 |
Why?
|
| Rats | 13 | 2017 | 23711 | 0.110 |
Why?
|
| Dyspnea | 1 | 2021 | 1352 | 0.110 |
Why?
|
| Stearates | 1 | 2012 | 6 | 0.100 |
Why?
|
| Pleural Diseases | 1 | 2013 | 137 | 0.100 |
Why?
|
| Rats, Inbred WF | 3 | 2004 | 138 | 0.100 |
Why?
|
| Cefazolin | 1 | 2013 | 94 | 0.100 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 6315 | 0.100 |
Why?
|
| Chest Tubes | 1 | 2013 | 152 | 0.100 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2004 | 516 | 0.100 |
Why?
|
| Pericardiocentesis | 1 | 2012 | 79 | 0.100 |
Why?
|
| Calcinosis | 1 | 2021 | 1476 | 0.100 |
Why?
|
| Water | 2 | 2016 | 1407 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2022 | 1351 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1347 | 0.100 |
Why?
|
| Biomimetics | 1 | 2013 | 173 | 0.100 |
Why?
|
| Adult | 25 | 2023 | 219994 | 0.100 |
Why?
|
| Bone Marrow | 3 | 1999 | 2912 | 0.100 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 58995 | 0.100 |
Why?
|
| Research Report | 1 | 2015 | 370 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2019 | 1248 | 0.100 |
Why?
|
| Liposomes | 1 | 2016 | 777 | 0.100 |
Why?
|
| Dimerization | 2 | 2006 | 891 | 0.100 |
Why?
|
| Robotics | 1 | 2019 | 874 | 0.100 |
Why?
|
| Injections, Intradermal | 1 | 2012 | 116 | 0.100 |
Why?
|
| Ultrasonics | 1 | 2013 | 207 | 0.100 |
Why?
|
| Tissue Distribution | 3 | 2023 | 2262 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 1995 | 1355 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2145 | 0.100 |
Why?
|
| Particle Size | 5 | 2015 | 1644 | 0.100 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2015 | 270 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2018 | 1268 | 0.100 |
Why?
|
| Esophagectomy | 2 | 2016 | 466 | 0.100 |
Why?
|
| Pneumonia | 1 | 2023 | 2131 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2008 | 1810 | 0.100 |
Why?
|
| Equipment and Supplies | 1 | 2013 | 275 | 0.090 |
Why?
|
| Diaphragm | 2 | 2010 | 351 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 6828 | 0.090 |
Why?
|
| Survival Rate | 6 | 2018 | 12808 | 0.090 |
Why?
|
| Consensus | 2 | 2023 | 3113 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 597 | 0.090 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 575 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 3 | 2013 | 2651 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 2 | 2023 | 412 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2012 | 720 | 0.080 |
Why?
|
| Melanoma | 2 | 2022 | 5697 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1832 | 0.080 |
Why?
|
| Insulinoma | 1 | 2009 | 121 | 0.080 |
Why?
|
| Disease Progression | 2 | 2020 | 13502 | 0.080 |
Why?
|
| ras Proteins | 1 | 2014 | 1052 | 0.080 |
Why?
|
| Endothelium, Vascular | 3 | 1990 | 4433 | 0.080 |
Why?
|
| Smoking | 2 | 2021 | 9073 | 0.080 |
Why?
|
| Time Factors | 9 | 2017 | 40165 | 0.080 |
Why?
|
| Pulmonary Emphysema | 1 | 2014 | 688 | 0.080 |
Why?
|
| Chondrosarcoma | 1 | 2011 | 296 | 0.080 |
Why?
|
| Cell Adhesion | 3 | 1990 | 3094 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 2014 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 716 | 0.080 |
Why?
|
| Thoracotomy | 2 | 2008 | 363 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 2 | 2008 | 1959 | 0.080 |
Why?
|
| Equipment Design | 3 | 2019 | 3520 | 0.080 |
Why?
|
| Contrast Media | 2 | 2014 | 5305 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2803 | 0.080 |
Why?
|
| Folic Acid | 1 | 2015 | 1309 | 0.080 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2008 | 71 | 0.080 |
Why?
|
| Job Satisfaction | 1 | 2012 | 539 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2018 | 2313 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2021 | 3598 | 0.080 |
Why?
|
| Lymphatic System | 2 | 2007 | 254 | 0.080 |
Why?
|
| Skin Transplantation | 3 | 2000 | 1083 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6544 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 643 | 0.070 |
Why?
|
| Microscopy | 1 | 2013 | 885 | 0.070 |
Why?
|
| Tracheal Diseases | 1 | 2008 | 115 | 0.070 |
Why?
|
| Iohexol | 1 | 2008 | 204 | 0.070 |
Why?
|
| Healthy People Programs | 1 | 2008 | 53 | 0.070 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2008 | 172 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2006 | 3387 | 0.070 |
Why?
|
| Bronchial Diseases | 1 | 2008 | 151 | 0.070 |
Why?
|
| Video Recording | 1 | 2012 | 955 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Fungal | 1 | 2006 | 8 | 0.070 |
Why?
|
| Chest Pain | 1 | 2014 | 1106 | 0.070 |
Why?
|
| Esophageal Perforation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 234 | 0.070 |
Why?
|
| Peritoneal Cavity | 1 | 2007 | 138 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11712 | 0.070 |
Why?
|
| Intubation | 1 | 2007 | 139 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2017 | 8555 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2013 | 4048 | 0.070 |
Why?
|
| Radiography | 2 | 2014 | 6965 | 0.070 |
Why?
|
| Interferon-gamma | 4 | 2008 | 3157 | 0.070 |
Why?
|
| Collagen | 2 | 2016 | 2636 | 0.070 |
Why?
|
| Daunorubicin | 1 | 2006 | 156 | 0.070 |
Why?
|
| Amphotericin B | 1 | 2006 | 142 | 0.070 |
Why?
|
| Aneurysm, False | 1 | 2008 | 257 | 0.070 |
Why?
|
| Antigens, Differentiation | 2 | 2004 | 911 | 0.070 |
Why?
|
| Cytokines | 3 | 2016 | 7343 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 1 | 2008 | 402 | 0.060 |
Why?
|
| Physicians, Family | 1 | 2008 | 349 | 0.060 |
Why?
|
| Mice, Inbred Strains | 3 | 2004 | 1763 | 0.060 |
Why?
|
| Life Style | 1 | 2017 | 3896 | 0.060 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 1263 | 0.060 |
Why?
|
| Endothelium | 1 | 1988 | 764 | 0.060 |
Why?
|
| Rupture, Spontaneous | 1 | 2006 | 356 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2006 | 204 | 0.060 |
Why?
|
| Asparaginase | 1 | 2006 | 240 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2007 | 575 | 0.060 |
Why?
|
| Spleen | 2 | 2004 | 2298 | 0.060 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2004 | 40 | 0.060 |
Why?
|
| HLA-D Antigens | 3 | 1990 | 134 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2008 | 1342 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2007 | 588 | 0.060 |
Why?
|
| Recurrence | 2 | 2015 | 8482 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4319 | 0.060 |
Why?
|
| Lipids | 1 | 2015 | 3336 | 0.060 |
Why?
|
| Carbonates | 1 | 2023 | 21 | 0.060 |
Why?
|
| Vincristine | 1 | 2006 | 1039 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7475 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1527 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2006 | 2313 | 0.060 |
Why?
|
| Radiography, Thoracic | 2 | 2008 | 1296 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 5397 | 0.060 |
Why?
|
| Lymphocytes | 2 | 1997 | 2611 | 0.050 |
Why?
|
| Gallstones | 1 | 2006 | 283 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 1 | 2004 | 232 | 0.050 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2004 | 198 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2016 | 11481 | 0.050 |
Why?
|
| Vancomycin | 1 | 2006 | 503 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 717 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2022 | 54303 | 0.050 |
Why?
|
| Esophagus | 2 | 2007 | 1023 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10827 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 12965 | 0.050 |
Why?
|
| Incidence | 5 | 2022 | 21392 | 0.050 |
Why?
|
| Reoperation | 2 | 2013 | 4291 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2018 | 5870 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 4742 | 0.050 |
Why?
|
| Boston | 2 | 2013 | 9280 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4490 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 215 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 585 | 0.050 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 812 | 0.050 |
Why?
|
| Attitude of Health Personnel | 2 | 2023 | 3865 | 0.050 |
Why?
|
| Macrophages | 1 | 2016 | 5745 | 0.050 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2022 | 126 | 0.050 |
Why?
|
| Parental Leave | 1 | 2002 | 91 | 0.050 |
Why?
|
| Cobalt | 1 | 2021 | 155 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14660 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1215 | 0.050 |
Why?
|
| Adhesives | 1 | 2021 | 65 | 0.050 |
Why?
|
| Tropolone | 1 | 2021 | 10 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2012 | 3106 | 0.050 |
Why?
|
| Quality of Life | 2 | 2023 | 13308 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 20080 | 0.050 |
Why?
|
| Neutropenia | 1 | 2006 | 884 | 0.050 |
Why?
|
| Sonication | 1 | 2021 | 79 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2008 | 1238 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 857 | 0.050 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2000 | 57 | 0.050 |
Why?
|
| Benzamides | 1 | 2006 | 1369 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 9467 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 3618 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2005 | 1809 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2004 | 1400 | 0.040 |
Why?
|
| Drug Compounding | 2 | 2011 | 246 | 0.040 |
Why?
|
| Syndrome | 1 | 2006 | 3280 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2006 | 14372 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 1993 | 2332 | 0.040 |
Why?
|
| Heart | 2 | 2022 | 4393 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2000 | 428 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 1975 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2011 | 24123 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 2 | 1996 | 248 | 0.040 |
Why?
|
| Risk Factors | 7 | 2023 | 74359 | 0.040 |
Why?
|
| Sheep | 1 | 2021 | 1441 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 8986 | 0.040 |
Why?
|
| Hydrogels | 2 | 2016 | 723 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 886 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2004 | 1557 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 3602 | 0.040 |
Why?
|
| Wound Healing | 1 | 2009 | 2788 | 0.040 |
Why?
|
| Clavicle | 1 | 2020 | 224 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2007 | 11903 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2004 | 4000 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2000 | 1060 | 0.040 |
Why?
|
| Disulfides | 1 | 2000 | 466 | 0.040 |
Why?
|
| Pericardium | 1 | 2002 | 675 | 0.040 |
Why?
|
| Decompression, Surgical | 1 | 2023 | 604 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2021 | 662 | 0.040 |
Why?
|
| Antigens, Heterophile | 1 | 1998 | 70 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2008 | 18957 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2022 | 3765 | 0.040 |
Why?
|
| Succinic Acid | 1 | 2018 | 84 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 1131 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 1155 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 1998 | 881 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2009 | 8158 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2007 | 3215 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 595 | 0.040 |
Why?
|
| Plasmids | 1 | 2022 | 2275 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1547 | 0.040 |
Why?
|
| Bone Marrow Purging | 1 | 1996 | 108 | 0.040 |
Why?
|
| Clonal Deletion | 1 | 1996 | 74 | 0.040 |
Why?
|
| Occupational Health | 1 | 2023 | 805 | 0.030 |
Why?
|
| Workflow | 1 | 2021 | 852 | 0.030 |
Why?
|
| Sex Factors | 1 | 2011 | 10547 | 0.030 |
Why?
|
| Adsorption | 1 | 2016 | 198 | 0.030 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1996 | 137 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2022 | 2209 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 967 | 0.030 |
Why?
|
| Piperazines | 1 | 2006 | 2525 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 5799 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2007 | 4353 | 0.030 |
Why?
|
| Gene Expression | 1 | 2008 | 7588 | 0.030 |
Why?
|
| Anniversaries and Special Events | 1 | 2016 | 94 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 1998 | 782 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 2543 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2013 | 1479 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 1273 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1998 | 733 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 1995 | 622 | 0.030 |
Why?
|
| Blood Cells | 1 | 1996 | 305 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7408 | 0.030 |
Why?
|
| Influenza A virus | 1 | 1998 | 457 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2138 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2006 | 3016 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 1996 | 532 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 1995 | 717 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2014 | 95 | 0.030 |
Why?
|
| Species Specificity | 1 | 1998 | 2418 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2015 | 1154 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2000 | 1354 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 1088 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1454 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1928 | 0.030 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 1993 | 25 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2013 | 66 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2014 | 330 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1998 | 662 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2024 | 41335 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12766 | 0.030 |
Why?
|
| Injections | 1 | 2016 | 830 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2013 | 161 | 0.030 |
Why?
|
| Rib Fractures | 1 | 2014 | 128 | 0.030 |
Why?
|
| Monoglycerides | 1 | 2012 | 10 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 597 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 1998 | 1254 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2022 | 3380 | 0.030 |
Why?
|
| Trachea | 1 | 1998 | 1082 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 7593 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 6853 | 0.030 |
Why?
|
| Flow Cytometry | 4 | 1996 | 5870 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 1297 | 0.030 |
Why?
|
| Polymethacrylic Acids | 1 | 2011 | 32 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 2821 | 0.020 |
Why?
|
| Decanoic Acids | 1 | 2011 | 68 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 1475 | 0.020 |
Why?
|
| Cell Division | 1 | 1999 | 4463 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2014 | 345 | 0.020 |
Why?
|
| Calcitonin | 1 | 1993 | 330 | 0.020 |
Why?
|
| Nanostructures | 1 | 2016 | 547 | 0.020 |
Why?
|
| Serum Albumin | 2 | 2005 | 674 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 2011 | 508 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1996 | 1247 | 0.020 |
Why?
|
| Air | 1 | 2012 | 186 | 0.020 |
Why?
|
| General Surgery | 1 | 2002 | 1678 | 0.020 |
Why?
|
| Cell Lineage | 2 | 1998 | 2533 | 0.020 |
Why?
|
| Government Regulation | 1 | 2015 | 525 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2021 | 1915 | 0.020 |
Why?
|
| SEER Program | 2 | 2007 | 1530 | 0.020 |
Why?
|
| Pheochromocytoma | 1 | 1993 | 328 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2011 | 660 | 0.020 |
Why?
|
| Gels | 1 | 2011 | 419 | 0.020 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1990 | 52 | 0.020 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1995 | 739 | 0.020 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1993 | 243 | 0.020 |
Why?
|
| Chitosan | 1 | 2011 | 131 | 0.020 |
Why?
|
| Phenotype | 2 | 2016 | 16546 | 0.020 |
Why?
|
| Central Venous Pressure | 1 | 2010 | 79 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2018 | 2493 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 29932 | 0.020 |
Why?
|
| HLA-DR Antigens | 2 | 1988 | 630 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 2056 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 1995 | 1577 | 0.020 |
Why?
|
| Cell Communication | 1 | 2016 | 1653 | 0.020 |
Why?
|
| Methylene Blue | 1 | 2009 | 157 | 0.020 |
Why?
|
| Students, Medical | 1 | 2002 | 1927 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2015 | 3105 | 0.020 |
Why?
|
| Antibodies | 1 | 1997 | 2421 | 0.020 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 1724 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 516 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1990 | 377 | 0.020 |
Why?
|
| Suction | 1 | 2010 | 263 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 3986 | 0.020 |
Why?
|
| Radiometry | 1 | 2014 | 813 | 0.020 |
Why?
|
| Immunosuppressive Agents | 2 | 1998 | 4166 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1347 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 4122 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10446 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 8950 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2015 | 1114 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 899 | 0.020 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 2007 | 37 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1385 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1993 | 733 | 0.020 |
Why?
|
| Barium | 1 | 2007 | 62 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 2086 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9585 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 1677 | 0.020 |
Why?
|
| Thoracic Duct | 1 | 2007 | 64 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1728 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6238 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15687 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1995 | 2415 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 4107 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1990 | 1608 | 0.020 |
Why?
|
| Adolescent | 3 | 2015 | 87810 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1958 | 0.020 |
Why?
|
| Urogenital Neoplasms | 1 | 2006 | 135 | 0.020 |
Why?
|
| Transplants | 1 | 2007 | 206 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2008 | 1032 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4899 | 0.020 |
Why?
|
| Curriculum | 1 | 2018 | 3718 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1995 | 2520 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 1996 | 2325 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2014 | 1870 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1990 | 1411 | 0.010 |
Why?
|
| Young Adult | 3 | 2015 | 58741 | 0.010 |
Why?
|
| Tissue Scaffolds | 1 | 2010 | 928 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2634 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 2005 | 390 | 0.010 |
Why?
|
| Lymphatic Vessels | 1 | 2007 | 358 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 1784 | 0.010 |
Why?
|
| Skin | 1 | 1995 | 4466 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 5253 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 3 | 1997 | 9185 | 0.010 |
Why?
|
| Aorta | 1 | 1989 | 2039 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10344 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 2006 | 533 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3529 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8624 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 2117 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 1683 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12960 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2017 | 22053 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2852 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2893 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1990 | 3707 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1990 | 5496 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2002 | 1098 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2006 | 951 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 3465 | 0.010 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 1998 | 19 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12427 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1990 | 4357 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1998 | 174 | 0.010 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 916 | 0.010 |
Why?
|
| Research | 1 | 2006 | 1974 | 0.010 |
Why?
|
| Intestines | 1 | 2007 | 1907 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1999 | 2094 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1994 | 1446 | 0.010 |
Why?
|
| Attitude | 1 | 2002 | 777 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9530 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1996 | 104 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 780 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2005 | 2256 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1996 | 467 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 36290 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 1895 | 0.010 |
Why?
|
| Disease Management | 1 | 2004 | 2514 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 6479 | 0.010 |
Why?
|
| Pregnancy | 3 | 2002 | 29749 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1998 | 1326 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8056 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 2882 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12159 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 2558 | 0.010 |
Why?
|
| Myocardium | 1 | 2002 | 4700 | 0.010 |
Why?
|
| HLA-DP Antigens | 1 | 1988 | 28 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 1720 | 0.000 |
Why?
|
| Fetus | 1 | 1996 | 1859 | 0.000 |
Why?
|
| HLA-DQ Antigens | 1 | 1988 | 211 | 0.000 |
Why?
|
| HLA-A Antigens | 1 | 1988 | 225 | 0.000 |
Why?
|
| HLA-B Antigens | 1 | 1988 | 331 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1994 | 2536 | 0.000 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1988 | 819 | 0.000 |
Why?
|
| Myocarditis | 1 | 1988 | 766 | 0.000 |
Why?
|
| Coronary Artery Disease | 1 | 1988 | 6659 | 0.000 |
Why?
|